Recombinant α-interferon in renal allograft recipients with chronic hepatitis C
Although chronic hepatitis C infection is one of the factors that can lead to morbidity and mortality in renal allograft recipients, treatment procedures have not been well documented. Interferon treatment has been shown to be effective in the normalization of biochemical hepatitis C and in the clea...
Gespeichert in:
| Veröffentlicht in: | Nephrology, dialysis, transplantation dialysis, transplantation, 1995-11, Vol.10 (11), p.2104-2106 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2106 |
|---|---|
| container_issue | 11 |
| container_start_page | 2104 |
| container_title | Nephrology, dialysis, transplantation |
| container_volume | 10 |
| creator | ÖZGÜR, O BOYACIOGLU, S TELATAR, H HABERAL, M |
| description | Although chronic hepatitis C infection is one of the factors that can lead to morbidity and mortality in renal allograft recipients, treatment procedures have not been well documented. Interferon treatment has been shown to be effective in the normalization of biochemical hepatitis C and in the clearing of hepatitis C virus RNA. However, little is known concerning the efficacy and safety of interferon treatment in renal allograft recipients with chronic hepatitis C. Interferon has also been accused of increasing renal allograft rejection.
Recombinant alpha-interferon in a dose of 4.5 million units three times per week was given to five renal-allograft recipients with chronic hepatitis C for 6 months. Besides biochemical investigations, liver histopathologies before and after the treatment course were also studied.
Interferon treatment was effective in two of the patients, in another two cases renal function deteriorated during the treatment. In the last case ALT increased again after cessation of interferon therapy.
We conclude that interferon seems to be moderately effective in treating chronic hepatitis C in renal allograft recipients, but a risk of renal functional deterioration and rejection remains. |
| doi_str_mv | 10.1093/ndt/10.11.2104 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77846751</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77846751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c274t-a322016e7c9d32ec51eb374793e8063c730f6cb1c08f3b701229844a0c2744d03</originalsourceid><addsrcrecordid>eNo9kM1KxDAUhYMo4zi6dSd0Ie46c_PTpl3K4B8MKKLrkqa3TqRNa5JBfCxfxGeydYqrey7nO2dxCDmnsKSQ85WtwmrUdMkoiAMypyKFmPEsOSTzAaAxJJAfkxPv3wEgZ1LOyCxLBacynZOnZ9RdWxqrbIh-vmNjA7oaXWcjYyOHVjWRapruzak6DL82vUEbfPRpwjbS2wE0Otpir4IJxkfrU3JUq8bj2XQX5PX25mV9H28e7x7W15tYMylCrDhjQFOUOq84Q51QLLkUMueYQcq15FCnuqQaspqXEihjeSaEgjEuKuALcrXv7V33sUMfitZ4jU2jLHY7X0iZiVQmdACXe1C7znuHddE70yr3VVAoxgmLYcI_TYtxwiFwMTXvyharf3zabPAvJ195rZraKauN_8dYTkXCJf8FVnt5hg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77846751</pqid></control><display><type>article</type><title>Recombinant α-interferon in renal allograft recipients with chronic hepatitis C</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><creator>ÖZGÜR, O ; BOYACIOGLU, S ; TELATAR, H ; HABERAL, M</creator><creatorcontrib>ÖZGÜR, O ; BOYACIOGLU, S ; TELATAR, H ; HABERAL, M</creatorcontrib><description>Although chronic hepatitis C infection is one of the factors that can lead to morbidity and mortality in renal allograft recipients, treatment procedures have not been well documented. Interferon treatment has been shown to be effective in the normalization of biochemical hepatitis C and in the clearing of hepatitis C virus RNA. However, little is known concerning the efficacy and safety of interferon treatment in renal allograft recipients with chronic hepatitis C. Interferon has also been accused of increasing renal allograft rejection.
Recombinant alpha-interferon in a dose of 4.5 million units three times per week was given to five renal-allograft recipients with chronic hepatitis C for 6 months. Besides biochemical investigations, liver histopathologies before and after the treatment course were also studied.
Interferon treatment was effective in two of the patients, in another two cases renal function deteriorated during the treatment. In the last case ALT increased again after cessation of interferon therapy.
We conclude that interferon seems to be moderately effective in treating chronic hepatitis C in renal allograft recipients, but a risk of renal functional deterioration and rejection remains.</description><identifier>ISSN: 0931-0509</identifier><identifier>ISSN: 1460-2385</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/10.11.2104</identifier><identifier>PMID: 8643176</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Alanine Transaminase - blood ; Antiviral Agents - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Female ; Hepatitis C - drug therapy ; Hepatitis C - enzymology ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Kidney Transplantation ; Male ; Medical sciences ; Transplantation, Homologous ; Viral diseases ; Viral hepatitis</subject><ispartof>Nephrology, dialysis, transplantation, 1995-11, Vol.10 (11), p.2104-2106</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2914537$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8643176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ÖZGÜR, O</creatorcontrib><creatorcontrib>BOYACIOGLU, S</creatorcontrib><creatorcontrib>TELATAR, H</creatorcontrib><creatorcontrib>HABERAL, M</creatorcontrib><title>Recombinant α-interferon in renal allograft recipients with chronic hepatitis C</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>Although chronic hepatitis C infection is one of the factors that can lead to morbidity and mortality in renal allograft recipients, treatment procedures have not been well documented. Interferon treatment has been shown to be effective in the normalization of biochemical hepatitis C and in the clearing of hepatitis C virus RNA. However, little is known concerning the efficacy and safety of interferon treatment in renal allograft recipients with chronic hepatitis C. Interferon has also been accused of increasing renal allograft rejection.
Recombinant alpha-interferon in a dose of 4.5 million units three times per week was given to five renal-allograft recipients with chronic hepatitis C for 6 months. Besides biochemical investigations, liver histopathologies before and after the treatment course were also studied.
Interferon treatment was effective in two of the patients, in another two cases renal function deteriorated during the treatment. In the last case ALT increased again after cessation of interferon therapy.
We conclude that interferon seems to be moderately effective in treating chronic hepatitis C in renal allograft recipients, but a risk of renal functional deterioration and rejection remains.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Female</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - enzymology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Kidney Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Transplantation, Homologous</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0931-0509</issn><issn>1460-2385</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1KxDAUhYMo4zi6dSd0Ie46c_PTpl3K4B8MKKLrkqa3TqRNa5JBfCxfxGeydYqrey7nO2dxCDmnsKSQ85WtwmrUdMkoiAMypyKFmPEsOSTzAaAxJJAfkxPv3wEgZ1LOyCxLBacynZOnZ9RdWxqrbIh-vmNjA7oaXWcjYyOHVjWRapruzak6DL82vUEbfPRpwjbS2wE0Otpir4IJxkfrU3JUq8bj2XQX5PX25mV9H28e7x7W15tYMylCrDhjQFOUOq84Q51QLLkUMueYQcq15FCnuqQaspqXEihjeSaEgjEuKuALcrXv7V33sUMfitZ4jU2jLHY7X0iZiVQmdACXe1C7znuHddE70yr3VVAoxgmLYcI_TYtxwiFwMTXvyharf3zabPAvJ195rZraKauN_8dYTkXCJf8FVnt5hg</recordid><startdate>19951101</startdate><enddate>19951101</enddate><creator>ÖZGÜR, O</creator><creator>BOYACIOGLU, S</creator><creator>TELATAR, H</creator><creator>HABERAL, M</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951101</creationdate><title>Recombinant α-interferon in renal allograft recipients with chronic hepatitis C</title><author>ÖZGÜR, O ; BOYACIOGLU, S ; TELATAR, H ; HABERAL, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c274t-a322016e7c9d32ec51eb374793e8063c730f6cb1c08f3b701229844a0c2744d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Female</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - enzymology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Kidney Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Transplantation, Homologous</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ÖZGÜR, O</creatorcontrib><creatorcontrib>BOYACIOGLU, S</creatorcontrib><creatorcontrib>TELATAR, H</creatorcontrib><creatorcontrib>HABERAL, M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ÖZGÜR, O</au><au>BOYACIOGLU, S</au><au>TELATAR, H</au><au>HABERAL, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant α-interferon in renal allograft recipients with chronic hepatitis C</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>1995-11-01</date><risdate>1995</risdate><volume>10</volume><issue>11</issue><spage>2104</spage><epage>2106</epage><pages>2104-2106</pages><issn>0931-0509</issn><issn>1460-2385</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Although chronic hepatitis C infection is one of the factors that can lead to morbidity and mortality in renal allograft recipients, treatment procedures have not been well documented. Interferon treatment has been shown to be effective in the normalization of biochemical hepatitis C and in the clearing of hepatitis C virus RNA. However, little is known concerning the efficacy and safety of interferon treatment in renal allograft recipients with chronic hepatitis C. Interferon has also been accused of increasing renal allograft rejection.
Recombinant alpha-interferon in a dose of 4.5 million units three times per week was given to five renal-allograft recipients with chronic hepatitis C for 6 months. Besides biochemical investigations, liver histopathologies before and after the treatment course were also studied.
Interferon treatment was effective in two of the patients, in another two cases renal function deteriorated during the treatment. In the last case ALT increased again after cessation of interferon therapy.
We conclude that interferon seems to be moderately effective in treating chronic hepatitis C in renal allograft recipients, but a risk of renal functional deterioration and rejection remains.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>8643176</pmid><doi>10.1093/ndt/10.11.2104</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-0509 |
| ispartof | Nephrology, dialysis, transplantation, 1995-11, Vol.10 (11), p.2104-2106 |
| issn | 0931-0509 1460-2385 1460-2385 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77846751 |
| source | MEDLINE; Oxford University Press Journals Digital Archive Legacy |
| subjects | Adult Alanine Transaminase - blood Antiviral Agents - therapeutic use Biological and medical sciences Chronic Disease Female Hepatitis C - drug therapy Hepatitis C - enzymology Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Kidney Transplantation Male Medical sciences Transplantation, Homologous Viral diseases Viral hepatitis |
| title | Recombinant α-interferon in renal allograft recipients with chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A47%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20%CE%B1-interferon%20in%20renal%20allograft%20recipients%20with%20chronic%20hepatitis%20C&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=%C3%96ZG%C3%9CR,%20O&rft.date=1995-11-01&rft.volume=10&rft.issue=11&rft.spage=2104&rft.epage=2106&rft.pages=2104-2106&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/10.11.2104&rft_dat=%3Cproquest_cross%3E77846751%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77846751&rft_id=info:pmid/8643176&rfr_iscdi=true |